• Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323(13):1239–1242. https://doi.org/10.1001/jama.2020.2648

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • World Health Organization (WHO) Weekly epidemiological update on COVID-19 – 15 March 2022. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—15-march-2022. Accessed 17 Mar 2022

  • Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, Hosein Z, Padda I, Mangat J, Altaf M (2020) Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2(8):1069–1076. https://doi.org/10.1007/s42399-020-00363-4

  • Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Albini A, Noonan DM, Pelosi G, Di Guardo G, Lombardo M (2020) The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based antihypertensive therapies-reply. Intern Emerg Med 15(8):1583–1584. https://doi.org/10.1007/s11739-020-02436-7

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhang P, Zhu L, Cai J et al (2020) Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 126(12):1671–1681. https://doi.org/10.1161/CIRCRESAHA.120.317134

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Felice C, Nardin C, Di Tanna GL, Grossi U, Bernardi E, Scaldaferri L, Romagnoli M, Tonon L, Cavasin P, Novello S, Scarpa R, Farnia A, De Menis E, Rigoli R, Cinetto F, Pauletto P, Agostini C, Rattazzi M (2020) Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian Cohort of 133 hypertensives. Am J Hypertens 33(10):944–948. https://doi.org/10.1093/ajh/hpaa096

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Fosbøl EL, Butt JH, Østergaard L, Andersson C, Selmer C, Kragholm K, Schou M, Phelps M, Gislason GH, Gerds TA, Torp-Pedersen C, Køber L (2020) Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA 324(2):168–177. https://doi.org/10.1001/jama.2020.11301

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hu J, Zhang X, Zhang X, Zhao H, Lian J, Hao S, Jia H, Yang M, Lu Y, Xiang D, Cai H, Zhang S, Gu J, Ye C, Yu G, Jin C, Zheng L, Yang Y, Sheng J (2020) COVID-19 is more severe in patients with hypertension; ACEI/ARB treatment does not influence clinical severity and outcome. J Infect 81(6):979–997. https://doi.org/10.1016/j.jinf.2020.05.056

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z (2020) Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 5(7):811–818. https://doi.org/10.1001/jamacardio.2020.1017

    Article 
    PubMed 

    Google Scholar
     

  • Lafaurie M, Martin-Blondel G, Delobel P, Charpentier S, Sommet A, Moulis G (2021) Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study. Fundam Clin Pharmacol 35(1):194–203. https://doi.org/10.1111/fcp.12613

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines. Available at https://www.strobe-statement.org/

  • Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

  • Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddhu S, Cheung AK, Xian W, Weintraub WS, Bress AP (2021) Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS ONE 16(4):e0248080. https://doi.org/10.1371/journal.pone.0248080

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ayed M, Borahmah AA, Yazdani A, Sultan A, Mossad A, Rawdhan H (2021) Assessment of clinical characteristics and mortality-associated factors in COVID-19 critical cases in Kuwait. Med Princ Pract 30(2):185–192. https://doi.org/10.1159/000513047

    Article 
    PubMed 

    Google Scholar
     

  • Senkal N, Meral R, Medetalibeyoğlu A, Konyaoğlu H, Kose M, Tukek T (2020) Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19. Anatol J Cardiol 24(1):21–29. https://doi.org/10.14744/AnatolJCardiol.2020.57431

  • Bae DJ, Tehrani DM, Rabadia SV, Frost M, Parikh RV, Calfon-Press M, Aksoy O, Umar S, Ardehali R, Rabbani A, Bokhoor P, Nsair A, Currier J, Tobis J, Fonarow GC, Dave R, Rafique AM (2020) Angiotensin converting enzyme inhibitor and angiotensin II receptor blocker use among outpatients diagnosed with COVID-19. Am J Cardiol 132:150–157. https://doi.org/10.1016/j.amjcard.2020.07.007

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Baker KF, Hanrath AT, van der Loeff IS, Tee SA, Capstick R, Marchitelli G, Li A, Barr A, Eid A, Ahmed S, Bajwa D, Mohammed O, Alderson N, Lendrem C, Lendrem DW, Covid-Control Group, Covid-Clinical Group, Pareja-Cebrian L, Welch A, Field J, Payne BAI, Taha Y, Price DA, Gibbins C, Schmid ML, Hunter E, Duncan CJA (2021) COVID-19 management in a UK NHS foundation trust with a high consequence infectious diseases centre: a retrospective analysis. Med Sci (Basel) 9(1):6. https://doi.org/10.3390/medsci9010006

  • Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M (2020) COVID-19 infection in kidney transplant recipients. Kidney Int 97(6):1076–1082. https://doi.org/10.1016/j.kint.2020.03.018

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bauer AZ, Gore R, Sama SR, Rosiello R, Garber L, Sundaresan D, McDonald A, Arruda P, Kriebel D (2021) Hypertension, medications, and risk of severe COVID-19: a Massachusetts community-based observational study. J Clin Hypertens (Greenwich) 23(1):21–27. https://doi.org/10.1111/jch.14101

    CAS 
    Article 

    Google Scholar
     

  • Bean DM, Kraljevic Z, Searle T, Bendayan R, Kevin O, Pickles A, Folarin A, Roguski L, Noor K, Shek A, Zakeri R, Shah AM, Teo JTH, Dobson RJB (2020) Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust. Eur J Heart Fail 22(6):967–974. https://doi.org/10.1002/ejhf.1924

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Braude P, Carter B, Short R, Vilches-Moraga A, Verduri A, Pearce L, Price A, Quinn TJ, Stechman M, Collins J, Bruce E, Einarsson A, Rickard F, Mitchell E, Holloway M, Hesford J, Barlow-Pay F, Clini E, Myint PK, Moug S, McCarthy K, Hewitt J (2020) The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19. Int J Cardiol Heart Vasc 31:100660. https://doi.org/10.1016/j.ijcha.2020.100660

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cannata F, Chiarito M, Reimers B, Azzolini E, Ferrante G, My I, Viggiani G, Panico C, Regazzoli D, Ciccarelli M, Voza A, Aghemo A, Li H, Wang Y, Condorelli G, Stefanini GG (2020) Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. Eur Heart J Cardiovasc Pharmacother 6(6):412–414. https://doi.org/10.1093/ehjcvp/pvaa056

    Article 
    PubMed 

    Google Scholar
     

  • Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, Amadou C, Arnault G, Baudoux F, Bauduceau B, Borot S, Bourgeon-Ghittori M, Bourron O, Boutoille D, Cazenave-Roblot F, Chaumeil C, Cosson E, Coudol S, Darmon P, Disse E, Ducet-Boiffard A, Gaborit B, Joubert M, Kerlan V, Laviolle B, Marchand L, Meyer L, Potier L, Prevost G, Riveline JP, Robert R, Saulnier PJ, Sultan A, Thébaut JF, Thivolet C, Tramunt B, Vatier C, Roussel R, Gautier JF, Gourdy P; CORONADO investigators (2020) Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 63(8):1500–1515. https://doi.org/10.1007/s00125-020-05180-x

  • Cetinkal G, Kocas BB, Ser OS, Kilci H, Yildiz SS, Ozcan SN, Verdi Y, Altinay M, Kilickesmez K (2020) The association between chronic use of renin–angiotensin–aldosterone system blockers and in-hospital adverse events among COVID-19 patients with hypertension. Sisli Etfal Hastan Tip Bul 54(4):399–404. https://doi.org/10.14744/SEMB.2020.15689

  • Chaudhri I, Koraishy FM, Bolotova O, Yoo J, Marcos LA, Taub E, Sahib H, Bloom M, Ahmad S, Skopicki H, Mallipattu SK (2020) Outcomes associated with the use of renin–angiotensin–aldosterone system blockade in hospitalized patients with SARS-CoV-2 Infection. Kidney360 1(8):801–809. https://doi.org/10.34067/kid.0003792020

  • Chen C, Wang F, Chen P, Jiang J, Cui G, Zhou N, Moroni F, Moslehi JJ, Ammirati E, Wang DW (2020) Mortality and pre-hospitalization use of renin-angiotensin system inhibitors in hypertensive COVID-19 patients. J Am Heart Assoc 9(21):e017736. https://doi.org/10.1161/JAHA.120.017736

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chen M, Fan Y, Wu X, Zhang, L, Guo T, Keqiong D, Cao J, Luo H, He T, Gong Y, Wang H, Wan J, Wang X, Lu Z (2020) Clinical characteristics and risk factors for fatal outcome in patients with 2019-coronavirus infected disease (COVID-19) in Wuhan, China (2/27/2020). https://doi.org/10.2139/ssrn.3546069

  • Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, Liu C, Xiong M, Deng A, Zhang Y, Zheng L, Huang K (2020) Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care 43(7):1399–1407. https://doi.org/10.2337/dc20-0660

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Choi HK, Koo HJ, Seok H, Jeon JH, Choi WS, Kim DJ, Park DW, Han E (2020) ARB/ACEI use and severe COVID-19: a nationwide case–control study. medRxiv 2020.06.12.20129916; https://doi.org/10.1101/2020.06.12.20129916

  • Christiansen CF, Pottegård A, Heide-Jørgensen U, Bodilsen J, Søgaard OS, Maeng M, Vistisen ST, Schmidt M, Lund LC, Reilev M, Hallas J, Voldstedlund M, Husby A, Thomsen MK, Johansen NB, Brun NC, Thomsen RW, Bøtker HE, Sørensen HT (2021) SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case–control and cohort analysis. Thorax 76(4):370–379. https://doi.org/10.1136/thoraxjnl-2020-215768

    Article 
    PubMed 

    Google Scholar
     

  • Conversano A, Melillo F, Napolano A, Fominskiy E, Spessot M, Ciceri F, Agricola E (2020) Renin–angiotensin–aldosterone system inhibitors and outcome in patients with SARS-CoV-2 pneumonia: a case series study. Hypertension 76(2):e10–e12. https://doi.org/10.1161/HYPERTENSIONAHA.120.15312

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Covino M, De Matteis G, Burzo ML, Santoro M, Fuorlo M, Sabia L, Sandroni C, Gasbarrini A, Franceschi F, Gambassi G; Gemelli Against COVID-19 Group (2020) Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19. Intern Med J 50(12):1483–1491. https://doi.org/10.1111/imj.15078

  • Desai A, Voza G, Paiardi S, Teofilo FI, Caltagirone G, Pons MR, Aloise M, Kogan M, Tommasini T, Savevski V, Stefanini G, Angelini C, Ciccarelli M, Badalamenti S, De Nalda AL, Aghemo A, Cecconi M, Martinelli Boneschi F, Voza A; Humanitas COVID-19 task force (2021) The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: a retrospective, observational study in Northern Italy. Int J Cardiol 324:249–254. https://doi.org/10.1016/j.ijcard.2020.09.062

  • Genet B, Vidal JS, Cohen A, Boully C, Beunardeau M, Marine Harlé L, Gonçalves A, Boudali Y, Hernandorena I, Bailly H, Lenoir H, Piccoli M, Chahwakilian A, Kermanach L, de Jong L, Duron E, Girerd X, Hanon O (2020) COVID-19 In-hospital mortality and use of renin–angiotensin system blockers in geriatrics patients. J Am Med Dir Assoc 21(11):1539–1545. https://doi.org/10.1016/j.jamda.2020.09.004

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Giacomelli A, Ridolfo AL, Milazzo L, Oreni L, Bernacchia D, Siano M, Bonazzetti C, Covizzi A, Schiuma M, Passerini M, Piscaglia M, Coen M, Gubertini G, Rizzardini G, Cogliati C, Brambilla AM, Colombo R, Castelli A, Rech R, Riva A, Torre A, Meroni L, Rusconi S, Antinori S, Galli M (2020) 30-Day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study. Pharmacol Res 158:104931. https://doi.org/10.1016/j.phrs.2020.104931

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R; Reggio Emilia COVID-19 Working Group (2020) Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy. PLoS ONE 15(8):e0238281. https://doi.org/10.1371/journal.pone.0238281

  • Hakeam HA, Alsemari M, Duhailib ZA, Ghonem L, Alharbi SA, Almutairy E, Sheraim NMB, Alsalhi M, Alhijji A, AlQahtani S, Khalid M, Barry M (2021) Association of angiotensin-converting enzyme inhibitors and angiotensin II blockers with severity of COVID-19: a multicentre, prospective study. J Cardiovasc Pharmacol Ther 26(3):244–252. https://doi.org/10.1177/1074248420976279

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Huang Z, Cao J, Yao Y, Jin X, Luo Z, Xue Y, Zhu C, Song Y, Wang Y, Zou Y, Qian J, Yu K, Gong H, Ge J (2020) The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. Ann Transl Med 8(7):430. https://doi.org/10.21037/atm.2020.03.229

  • Ip A, Parikh K, Parrillo JE, Mathura S, Hansen E, Sawczuk IS, Goldberg SL (2020) Hypertension and renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. medRxiv 2020.04.24.20077388. https://doi.org/10.1101/2020.04.24.20077388

  • Jung C, Bruno RR, Wernly B, Joannidis M, Oeyen S, Zafeiridis T, Marsh B, Andersen FH, Moreno R, Fernandes AM, Artigas A, Pinto BB, Schefold J, Wolff G, Kelm M, De Lange DW, Guidet B, Flaatten H, Fjølner J; COVIP study group (2021) Inhibitors of the renin–angiotensin–aldosterone system and COVID-19 in critically ill elderly patients. Eur Heart J Cardiovasc Pharmacother 7(1):76–77. https://doi.org/10.1093/ehjcvp/pvaa083

  • Jung SY, Choi JC, You SH, Kim WY (2020) Association of renin-angiotensin-aldosterone system inhibitors with coronavirus disease 2019 (COVID-19)-related outcomes in Korea: a nationwide population-based cohort study. Clin Infect Dis 71(16):2121–2128. https://doi.org/10.1093/cid/ciaa624

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Khan KS, Reed-Embleton H, Lewis J, Bain P, Mahmud S (2020) Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. A multi-centre observational study. Scott Med J 65(4):149–153. https://doi.org/10.1177/0036933020951926

  • Khera R, Clark C, Lu Y, Guo Y, Ren S, Truax B, Spatz ES, Murugiah K, Lin Z, Omer SB, Vojta D, Krumholz HM (2020) Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease-19. medRxiv. 19:2020.05.17.20104943. https://doi.org/10.1101/2020.05.17.20104943

  • Kim JH, Baek YH, Lee H, Choe YJ, Shin HJ, Shin JY (2021) Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study. Epidemiol Health 43:e2021004. https://doi.org/10.4178/epih.e2021004

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Lam KW, Chow KW, Vo J, Hou W, Li H, Richman PS, Mallipattu SK, Skopicki HA, Singer AJ, Duong TQ (2020) Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome. J Infect Dis 222(8):1256–1264. https://doi.org/10.1093/infdis/jiaa447

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Lee HY, Ahn J, Kang CK, Won SH, Park JH, Kang CH, Chung KH, Joh JS, Bang J, Yoo, H, Park O, Oh M (2020) Association of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19-related outcome (4/1/2020). https://doi.org/10.2139/ssrn.3569837

  • Li J, Wang X, Chen J, Zhang H, Deng A (2020) Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan. China JAMA Cardiol 5(7):825–830. https://doi.org/10.1001/jamacardio.2020.1624

    Article 
    PubMed 

    Google Scholar
     

  • Liabeuf S, Moragny J, Bennis Y, Batteux B, Brochot E, Schmit JL, Lanoix JP, Andrejak C, Ganry O, Slama M, Maizel J, Mahjoub Y, Masmoudi K, Gras-Champel V (2021) Association between renin–angiotensin system inhibitors and COVID-19 complications. Eur Heart J Cardiovasc Pharmacother 7(5):426–434. https://doi.org/10.1093/ehjcvp/pvaa062

    Article 
    PubMed 

    Google Scholar
     

  • Lim JH, Cho JH, Jeon Y, Kim JH, Lee GY, Jeon S, Noh HW, Lee YH, Lee J, Chang HH, Jung HY, Choi JY, Park SH, Kim CD, Kim YL, Kim SW (2020) Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study. Sci Rep 10(1):20250. https://doi.org/10.1038/s41598-020-76915-4

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • López-Otero D, López-Pais J, Cacho-Antonio CE, Antúnez-Muiños PJ, González-Ferrero T, Pérez-Poza M, Otero-García Ó, Díaz-Fernández B, Bastos-Fernández M, Bouzas-Cruz N, Sanmartín-Pena XC, Varela-Román A, Portela-Romero M, Valdés-Cuadrado L, Pose-Reino A, González-Juanatey JR (2021) Impacto de los inhibidores de la enzima de conversión de la angiotensina y los antagonistas del receptor de la angiotensina II en la COVID-19 en una población occidental. Registro CARDIOVID [Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry]. Rev Esp Cardiol 74(2):175–182. https://doi.org/10.1016/j.recesp.2020.05.030

  • Matsuzawa Y, Ogawa H, Kimura K, Konishi M, Kirigaya J, Fukui K, Tsukahara K, Shimizu H, Iwabuchi K, Yamada Y, Saka K, Takeuchi I, Hirano T, Tamura K (2020) Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study. Hypertens Res 43(11):1257–1266. https://doi.org/10.1038/s41440-020-00535-8

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, Carmona-Rubio AE, Jacob M, Procop GW, Harrington S, Milinovich A, Svensson LG, Jehi L, Young JB, Chung MK (2020) Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 5(9):1020–1026. https://doi.org/10.1001/jamacardio.2020.1855

    Article 
    PubMed 

    Google Scholar
     

  • Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, Gao H, Liu L, Zhang G (2020) Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 9(1):757–760. https://doi.org/10.1080/22221751.2020.1746200

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Negreira-Caamaño M, Piqueras-Flores J, Martínez-DelRio J, Nieto-Sandoval-Martin-DeLaSierra P, Aguila-Gordo D, Mateo-Gomez C, Salas-Bravo D, Rodriguez-Martinez M, Negreira-Caamaño M (2020) Impact of treatment with renin-angiotensin system inhibitors on clinical outcomes in hypertensive patients hospitalized with COVID-19. High Blood Press Cardiovasc Prev 27(6):561–568. https://doi.org/10.1007/s40292-020-00409-7

  • Oussalah A, Gleye S, Clerc Urmes I, Laugel E, Callet J, Barbé F, Orlowski S, Malaplate C, Aimone-Gastin I, Caillierez BM, Merten M, Jeannesson E, Kormann R, Olivier JL, Rodriguez-Guéant RM, Namour F, Bevilacqua S, Losser MR, Levy B, Kimmoun A, Gibot S, Thilly N, Frimat L, Schvoerer E, Guéant JL (2020) Long-term ACE inhibitor/ARB use is associated with severe renal dysfunction and acute kidney injury in patients with severe COVID-19: results from a referral center cohort in the Northeast of France. Clin Infect Dis 71(9):2447–2456. https://doi.org/10.1093/cid/ciaa677

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Pan W, Zhang J, Wang M, Ye J, Xu Y, Shen B, He H, Wang Z, Ye D, Zhao M, Luo Z, Liu M, Zhang P, Gu J, Liu M, Li D, Liu J, Wan J (2020) Clinical features of COVID-19 in patients with essential hypertension and the impacts of renin-angiotensin-aldosterone system inhibitors on the prognosis of COVID-19 patients. Hypertension 76(3):732–741. https://doi.org/10.1161/HYPERTENSIONAHA.120.15289

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, Hauser RG, Schultze A, Jarvis CI, Holodniy M, Lo Re V, Akgun KM, Crothers K, Taddei TH, Freiberg MS, Justice AC (2020) Covid-19 testing, hospital admission, and intensive care among 2,026,227 United States veterans aged 54–75 years. medRxiv. 14:2020.04.09.20059964. https://doi.org/10.1101/2020.04.09.20059964

  • Rezel-Potts E, Douiri A, Chowienczyk PJ, Gulliford MC (2021) Antihypertensive medications and COVID-19 diagnosis and mortality: population-based case-control analysis in the United Kingdom. Br J Clin Pharmacol 87(12):4598–4607. https://doi.org/10.1111/bcp.14873

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 323(20):2052–2059. https://doi.org/10.1001/jama.2020.6775

  • Rodilla E, Saura A, Jiménez I, Mendizábal A, Pineda-Cantero A, Lorenzo-Hernández E, Fidalgo-Montero MDP, López-Cuervo JF, Gil-Sánchez R, Rabadán-Pejenaute E, Abella-Vázquez L, Giner-Galvañ V, Solís-Marquínez MN, Boixeda R, Peña-Fernández A, Carrasco-Sánchez FJ, González-Moraleja J, Torres-Peña JD, Guisado-Espartero ME, Escobar-Sevilla J, Guzmán-García M, Martín-Escalante MD, Martínez-González ÁL, Casas-Rojo JM, Gómez-Huelgas R (2020) Association of hypertension with all-cause mortality among hospitalized patients with COVID-19. J Clin Med 9(10):3136. https://doi.org/10.3390/jcm9103136

    CAS 
    Article 
    PubMed Central 

    Google Scholar
     

  • Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S (2020) Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19. JAMA Netw Open 3(12):e2029058. https://doi.org/10.1001/jamanetworkopen.2020.29058

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sardu C, Maggi P, Messina V, Iuliano P, Sardu A, Iovinella V, Paolisso G, Marfella R (2020) Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of Southern Italy. J Am Heart Assoc 9(17):e016948. https://doi.org/10.1161/JAHA.120.016948

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Selçuk M, Çınar T, Keskin M, Çiçek V, Kılıç Ş, Kenan B, Doğan S, Asal S, Günay N, Yıldırım E, Keskin Ü, Orhan AL (2020) Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients? Clin Exp Hypertens 42(8):738–742. https://doi.org/10.1080/10641963.2020.1783549

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Shah P, Owens J, Franklin J, Jani Y, Kumar A, Doshi R (2020) Baseline use of angiotensin-converting enzyme inhibitor/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients. J Hypertens 38(12):2537–2541. https://doi.org/10.1097/HJH.0000000000002584

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Soleimani A, Kazemian S, Karbalai Saleh S, Aminorroaya A, Shajari Z, Hadadi A, Talebpour M, Sadeghian H, Payandemehr P, Sotoodehnia M, Bahreini M, Najmeddin F, Heidarzadeh A, Zivari E, Ashraf H (2020) Effects of angiotensin receptor blockers (ARBs) on in-hospital outcomes of patients with hypertension and confirmed or clinically suspected COVID-19. Am J Hypertens 33(12):1102–1111. https://doi.org/10.1093/ajh/hpaa149

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Son M, Seo J, Yang S (2020) Association between renin-angiotensin-aldosterone system inhibitors and COVID-19 infection in South Korea. Hypertension 76(3):742–749. https://doi.org/10.1161/HYPERTENSIONAHA.120.15464

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Tan ND, Qiu Y, Xing XB, Ghosh S, Chen MH, Mao R (2020) Associations between angiotensin-converting enzyme inhibitors and angiotensin II receptor blocker use, gastrointestinal symptoms, and mortality among patients with COVID-19. Gastroenterology 159(3):1170-1172.e1. https://doi.org/10.1053/j.gastro.2020.05.034

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Wang Z, Zhang D, Wang S, Jin Y, Huan J, Wu Y, Xia C, Li Z, Qi X, Zhang D, Han X, Zhu X, Qu Y, Wang Q (2020) A retrospective study from 2 centers in china on the effects of continued use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with hypertension and COVID-19. Med Sci Monit 26:e926651. https://doi.org/10.12659/MSM.926651

  • Xu J, Huang C, Fan G, Liu Z, Shang L, Zhou F, Wang Y, Yu J, Yang L, Xie K, Huang Z, Huang L, Gu X, Li H, Zhang Y, Wang Y, Hayden FG, Horby PW, Cao B, Wang C (2020) Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Front Med 14(5):601–612. https://doi.org/10.1007/s11684-020-0800-y

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, Cai J, Yang R, Han J, Huang Y, He S (2020) Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study. Hypertension 76(1):51–58. https://doi.org/10.1161/HYPERTENSIONAHA.120.15143

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Yuan Y, Liu D, Zeng S, Wang S, Xu S, Wang Y, Yu R, Gao Y, Li H, Feng X, Zhou N, Zhao C, Gao Q (2020) In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension. J Infect 81(5):816–846. https://doi.org/10.1016/j.jinf.2020.08.014

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zeng Z, Sha T, Zhang Y, Wu F, Hu H, Li H (2020) Hypertension in patients hospitalized with COVID-19 in Wuhan, China: a single-center retrospective observational study. MedRxiv. https://doi.org/10.1101/2020.04.06.20054825

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, Xia M, Chen MM, Cheng X, Zhang X, Guo D, Peng Y, Ji YX, Chen J, She ZG, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu M, Chen M, Zhang XJ, Wang X, Touyz RM, Xia J, Zhang BH, Huang X, Yuan Y, Loomba R, Liu PP, Li H (2020) Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 126(12):1671–1681. https://doi.org/10.1161/CIRCRESAHA.120.317134

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhong Y, Zhao L, Wu G, Hu C, Wu C, Xu M, Dong H, Zhang Q, Wang G, Yu B, Lv J, Wu C, Zhang S, Cao C, Shu L, Pan Y, Liu X, Wu F (2020) Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study. J Int Med Res 48(12):300060520979151. https://doi.org/10.1177/0300060520979151

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Zhou F, Liu YM, Xie J, Li H, Lei F, Yang H, Qin JJ, Cai J, Zhang XJ, Wu B, Xia M, Xiang D, Yang C, Ma X, Xu Q, Lu Z, Lu H, Xia X, Wang D, Liao X, Peng G, Yang J, Huang X, Zhang BH, Yuan Y, Wei X, Liu PP, Wang Y, Zhang P, She ZG, Xia J, Li H (2020) Comparative impacts of ACE (angiotensin-converting enzyme) inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality. Hypertension 76(2):e15–e17. https://doi.org/10.1161/HYPERTENSIONAHA.120.15622

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111(20):2605–2610. https://doi.org/10.1161/CIRCULATIONAHA.104.510461

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Dai XC, An ZY, Wang ZY, Wang ZZ, Wang YR. (2021) Associations Between the Use of Renin-Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies. Front Cardiovasc Med 8:609857. https://doi.org/10.3389/fcvm.2021.609857

  • Singh R, Rathore SS, Khan H, Bhurwal A, Sheraton M, Ghosh P, Anand S, Makadia J, Ayesha F, Mahapure KS, Mehra I, Tekin A, Kashyap R, Bansal V (2022) Mortality and severity in COVID-19 patients on ACEIs and ARBs—a systematic review, meta-analysis, and meta-regression analysis. Front Med (Lausanne) 10(8):703661. https://doi.org/10.3389/fmed.2021.703661

    Article 

    Google Scholar
     

  • Hasan SS, Kow CS, Hadi MA, Zaidi STR, Merchant HA (2020) Mortality and disease severity among COVID-19 patients receiving renin–angiotensin system inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs 20(6):571–590. https://doi.org/10.1007/s40256-020-00439-5

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wang Y, Chen B, Li Y, Zhang L, Wang Y, Yang S, Xiao X, Qin Q (2021) The use of renin–angiotensin–aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: a systematic review and meta-analysis. J Med Virol 93(3):1370–1377. https://doi.org/10.1002/jmv.26625

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Azad GN, Kumar A (2022) ACEi/ARB and deaths of COVID-19 patients. Curr Hypertens Rev. https://doi.org/10.2174/1573402118666220407093332

    Article 
    PubMed 

    Google Scholar
     

  • Srivastava R, Kumar A (2021) Use of aspirin in reduction of mortality of COVID-19 patients: a meta-analysis. Int J Clin Pract 75:e14515. https://doi.org/10.1111/ijcp.14515

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Vitalakumar D, Sharma A, Kumar A, Flora SJS (2021) Neurological Manifestations in COVID-19 Patients: a meta-analysis. ACS Chem Neurosci 12:2776–2797. https://doi.org/10.1021/acschemneuro.1c00353

    CAS 
    Article 

    Google Scholar
     

  • Thakur M, Datusalia AK, Kumar A (2022) Use of steroids in COVID-19 patients: a meta-analysis. Eur J Pharmacol 914:174579. https://doi.org/10.1016/j.ejphar.2021.174579

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Rights and permissions

    Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

    Disclaimer:

    This article is autogenerated using RSS feeds and has not been created or edited by OA JF.

    Click here for Source link (https://www.springeropen.com/)